Norges Bank Buys New Position in ICU Medical, Inc. (NASDAQ:ICUI)

Norges Bank purchased a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 258,758 shares of the medical instruments supplier’s stock, valued at approximately $40,151,000. Norges Bank owned about 1.06% of ICU Medical as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the stock. FMR LLC increased its stake in ICU Medical by 2,676.6% during the 3rd quarter. FMR LLC now owns 104,094 shares of the medical instruments supplier’s stock valued at $18,968,000 after purchasing an additional 100,345 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of ICU Medical by 16.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,997 shares of the medical instruments supplier’s stock valued at $1,275,000 after acquiring an additional 991 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in ICU Medical by 4.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 42,742 shares of the medical instruments supplier’s stock worth $7,788,000 after acquiring an additional 1,751 shares during the last quarter. Captrust Financial Advisors lifted its position in ICU Medical by 54.2% during the 3rd quarter. Captrust Financial Advisors now owns 2,969 shares of the medical instruments supplier’s stock worth $541,000 after acquiring an additional 1,043 shares during the period. Finally, State Street Corp increased its holdings in shares of ICU Medical by 9.3% in the third quarter. State Street Corp now owns 907,607 shares of the medical instruments supplier’s stock valued at $165,384,000 after purchasing an additional 77,506 shares during the period. Institutional investors and hedge funds own 96.10% of the company’s stock.

Wall Street Analysts Forecast Growth

ICUI has been the subject of a number of research reports. Jefferies Financial Group raised ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price for the company in a report on Wednesday, December 11th. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Friday. Finally, Raymond James set a $97.00 target price on shares of ICU Medical in a research report on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $168.67.

ICU Medical Trading Down 1.6 %

ICU Medical stock opened at $139.32 on Friday. The firm has a market cap of $3.42 billion, a PE ratio of -30.49 and a beta of 0.73. ICU Medical, Inc. has a 12 month low of $93.36 and a 12 month high of $196.26. The stock’s 50 day simple moving average is $151.64 and its two-hundred day simple moving average is $162.55. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.